Pancreatic Elastase Testing Market Analysis

The market is segmented by application into cystic fibrosis, diabetes mellitus, chronic pancreatitis, pancreatic insufficiency, and others out of which, the chronic pancreatitis segment is anticipated to hold a substantial share in the global pancreatic elastase testing market over the forecast period. The growth of the segment can be accredited to the high prevalence of chronic pancreatitis across the globe, along with the rising cases of pancreatic cancer. Pancreatitis, if left untreated, can lead to cancer in the pancreas. The growth in the average alcohol consumption, as a part of the changing modern lifestyle, is also estimated to encourage the segment growth, as alcohol consumption is a major cause for chronic pancreatitis.

Our in-depth analysis of the global pancreatic elastase testing market includes the following segments

By Application	Cystic Fibrosis Diabetes Mellitus Chronic Pancreatitis Pancreatic Insufficiency Others
By End-User	Diagnostic Centers Hospitals and Clinics Pathology Laboratories Research Centers Others

Frequently Asked Questions (FAQ)

The increasing prevalence of chronic pancreatitis is estimated to boost the market growth.

The market is anticipated to attain a CAGR of ~6% over the forecast period, i.e., 2022 â€“ 2031.

The lack of researchers and practitioners in pathological science is estimated to hamper the market growth.

The North America region is anticipated to provide more business opportunities over the forecast period owing to the growing prevalence of chronic pancreatitis in the region.

The major players in the market are Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd., Hologic, Inc., BIOMERIEUX PLC, Bioserv Diagnostics Gmbh, Novozymes A/S, AB Enzymes GmbH, and Buhlmann Diagnostics Corp.

Pancreatic Elastase Testing Market Analysis